Clinical Research Directory
Browse clinical research sites, groups, and studies.
Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease
Sponsor: Centre Hospitalier Universitaire, Amiens
Summary
A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. Finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. The objectives of this project are to Determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (Neurovascular Unit) and cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), Fronto Temporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)) and to define the lesion determinants with VBM and VLSM
Key Details
Gender
All
Age Range
40 Years - 85 Years
Study Type
OBSERVATIONAL
Enrollment
129
Start Date
2021-07-16
Completion Date
2027-07-16
Last Updated
2026-05-13
Healthy Volunteers
No
Interventions
quick tests
New quick tests are * Batterie MindPlus (Brevet n° FR1908081, Suarez 2019) is a quick reaction time battery and * Minimal Cognitive Evaluation (MCE) test (Sardi et al, 2019) is a cognitive screening tests including a specific assessment of slowing
Locations (1)
CHU Amiens
Amiens, France